Company Announcements

Tempus AI Reports Revenue Growth and Key Acquisition

The latest announcement is out from Tempus AI, Inc. Class A ( (TEM) ).

Tempus AI, a company at the forefront of AI-driven precision medicine, reported a 33% year-over-year revenue increase to $180.9 million for Q3 2024 and announced its acquisition of Ambry Genetics to enhance its genetic testing capabilities. Despite a net loss of $75.8 million, Tempus projects a full-year revenue of $700 million, reflecting a 32% growth. The acquisition aims to expand Tempus’ testing portfolio and further its strategy of using data to innovate in clinical and scientific fields, tapping into new areas like pediatrics and women’s health.

See more data about TEM stock on TipRanks’ Stock Analysis page.

Related Articles
TheFlyTempus AI reports Q3 EPS (46c), consensus (31c)
TheFlyTempus AI sees FY24 revenue approx $700M, consensus $698.09M
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App